



UNIVERSITY OF LEEDS

This is a repository copy of *Widening gap in life expectancy between patients with heart failure living in 2 most and least deprived areas: a longitudinal cohort study.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/226888/>

Version: Accepted Version

Article:

Brown, O.I., Drozd, M., MacGowan, H. et al. (14 more authors) (Accepted: 2025) Widening gap in life expectancy between patients with heart failure living in 2 most and least deprived areas: a longitudinal cohort study. BMC Medicine. ISSN 1741-7015 (In Press)

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Widening gap in life expectancy between patients with heart failure living in most and least deprived areas: a longitudinal cohort study.

Brown OI¹, Drozd M¹, MacGowan H¹, McGinlay M², Burgess R², Straw S¹, Simms AD², Gatenby VK², Sengupta A², Walker AMN², Saunderson C², Paton MF¹, Bridge KI¹, Gierula J¹, Witte KK¹, Cubbon RM¹, Kearney MT¹

¹ Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, UK

² Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Corresponding author:

Professor Mark T Kearney

LIGHT Laboratories 7.04, University of Leeds, Clarendon Way, Leeds, LS2 9JT,
United Kingdom

Email: m.t.kearney@leeds.ac.uk

Abstract

Background

Socioeconomic deprivation is associated with adverse clinical outcomes in patients with heart failure (HF). However, in the context of improved medical and device therapy for HF, it is unknown whether the influence of socioeconomic deprivation on HF outcomes is changing over time, especially in relation to evolving life expectancy patterns in the general population. Therefore, we aimed to describe temporal trends in the association of socioeconomic deprivation with loss of actuarially predicted life expectancy amongst ambulatory patients with HF.

Methods

Between 2006 and 2014, 1802 patients (73.2% male, mean age 69.6 years) with HF and left ventricular ejection fraction $\leq 45\%$ were consecutively recruited across four hospitals in the United Kingdom (UK). Patients were stratified into socioeconomic deprivation tertiles defined by the UK Index of Multiple Deprivation (IMD) score with IMD tertile 1 denoting the least deprived, and IMD tertile 3 the most deprived. The primary outcome was all-cause mortality, and relative survival predictions – in relation to age- and sex-matched background mortality rates - were calculated using UK National Life Tables. Relative survival was illustrated in terms of excess mortality risk and years of life expectancy lost. Recruitment period was split into three-year intervals (2006-2008; 2009-2011 and 2012-2014).

Results

During a median follow-up of 5.0 years, 1,302 participants (72.3%) died. Unadjusted mortality rate was highest in tertile 2. However, adjusted to the age-sex matched UK population, a stepwise increase in excess mortality risk was observed across tertiles, with tertile 1 experiencing an excess mortality risk of 11.1% (95% CI: 6.1%-16.1%) and tertile 3 24.2% (95% CI: 19.4%-28.0%). This corresponded to a loss of life expectancy of 1.76 years (95% CI: 1.50-2.03) for tertile 1 and 2.30 years (95% CI: 2.03-2.57) for tertile 3 over a ten-year period. We observed disparity in actuarial survival between tertiles over time, with participants in tertile 1 losing less life expectancy at ten years compared to those in tertiles 2 and 3. However this was only statistically significant for those recruited between 2012-2014 ($p < 0.05$).

Conclusions

The impact of socioeconomic deprivation on HF outcomes in an unselected diverse UK population appears to have worsened over time.

Keywords

Heart failure – Socioeconomic deprivation – Actuarial survival – Health inequality

Background

Chronic heart failure (HF) is a clinical syndrome defined by dyspnoea, venous congestion and elevated natriuretic peptides, leading to increased hospitalisation and premature mortality. [1] While the standardised incidence of HF is declining, the prevalence and burden of HF in the United Kingdom (UK), both to individuals and society continues to grow. This is driven by an aging population and improved survival following the widespread adoption of comprehensive medical and device therapy for heart failure with reduced ejection fraction (HFrEF). [2,3] Despite this, there remain inequalities in access to services and therapies for people with HF within the UK. [4]

Socioeconomic deprivation is associated with higher mortality and increased rates of hospital admissions in HF patients. Moreover, patients facing socioeconomic deprivation often encounter multilevel barriers to healthcare contributing to healthcare inequalities. [5–7] At the systems level, healthcare facilities serving low-income populations frequently lack adequate resources, particularly regarding access to primary care and specialty services in underserved areas. This may delay diagnosis and treatment initiation, leading to more advanced disease progression at the time of presentation. [8,9]. Whilst at a provider level, healthcare worker implicit biases, stereotyping, and communication barriers can influence how patients are perceived and treated, potentially resulting in unequal care. [10]

Socioeconomic deprivation is linked to higher rates of comorbidities, such as diabetes, hypertension, and obesity, which complicate the management of HF and

1 contribute to poorer outcomes. [2,11] Furthermore, patients in lower socioeconomic
2 groups may face barriers to adhering to prescribed therapies, such as medication
3 costs or limited health literacy, reducing the effectiveness of evidence-based
4 treatments. [12] Psychosocial stress, poor nutrition, and limited social support
5 networks further exacerbate the burden of HF in deprived populations, contributing to
6 the observed disparities in outcomes. [12]

7
8 However, the effect of socioeconomic deprivation on HF mortality over time remains
9 unknown and challenging to assess given changing rates in comorbidities and an
10 aging population. Moreover, previous studies have demonstrated marked
11 discrepancy between patient-predicted survival and survival estimates from
12 prognostic models, highlighting the importance of improving communication around
13 this critical and sensitive issue. [13]

14
15 Given this, we aimed to compare the observed survival of individuals with HF to that
16 of an age- and sex- matched actuarial control population, and to assess the
17 association of socioeconomic deprivation with this over time.

18 19 **Methods**

20
21 The design of the United Kingdom Heart Failure Evaluation and Assessment of Risk
22 Trial (UK-HEART-2), a prospective cohort study of ambulatory heart failure patients
23 within the United Kingdom has been previously published. [14,15] The overarching
24 aim of UK-HEART-2 was to identify prognostic markers in patients with HF and

1 reduced left ventricular ejection fraction (LVEF), receiving contemporary evidence-
2 based therapy.

3
4 Between July 2006 and December 2014, consecutive patients with stable symptoms
5 and/or signs of HF for at least 3 months and an LVEF $\leq 45\%$ under the care of four
6 specialist heart failure outpatient clinics within West Yorkshire in the United Kingdom
7 were enrolled. The secondary care hospital where patients were reviewed was
8 determined by their residential postcode, which was also used to calculate their
9 Index of Multiple Deprivation (IMD) score. All patients provided informed written
10 consent and the study was conducted in accordance with the principles outlined in
11 the Declaration of Helsinki. Ethical approval of the study was granted by the Leeds
12 West Research Ethics Committee prior to study commencement.

13
14 All patients underwent transthoracic echocardiography, resting 12-lead ECGs, and
15 blood testing for measurement of full blood count, electrolytes and serum creatinine.
16 Functional status was assessed using the New York Heart Association (NYHA)
17 classification. Total daily doses of angiotensin converting enzymes inhibitors,
18 angiotensin receptor blockers, beta-blockers and loop diuretic were collected at
19 recruitment; these were normalised to maximum licensed HF dose as previously
20 described. [16] Receipt of cardiac resynchronisation therapy or implantable
21 cardioverter defibrillator was assessed during the 6-month period after recruitment.

22
23 For our secondary analysis looking at the association of socioeconomic deprivation
24 with mortality over time, we split recruitment period into three yearly intervals (2006
25 to 2008; 2009 to 2011 and 2012 to 2014).

Socioeconomic status

Socioeconomic status was determined using individual patient postal codes, which were mapped to one of 32,482 geographical regions, each representing approximately 1,500 people. These regions were defined according to the IMD which measures local socioeconomic deprivation. Since our cohort recruitment spanned three official IMD updates (2007, 2010, and 2015), we assigned the IMD rank/score based on the update closest to each patient's recruitment date. IMD provides a current index of socioeconomic deprivation, compiled from data collected by various UK government and non-government agencies, and is recognized as a valid indicator of overall deprivation at the geographical level. It generates a composite deprivation score for each region, weighted by domains such as income (22.5%), employment (22.5%), health and disability (13.5%), education, skills, and training (13.5%), barriers to housing and services (9.3%), crime (9.3%), and living environment (9.3%). In our analysis, participants were divided into tertiles with tertile 1 denoting the least deprived, and tertile 3 the most deprived.

Outcome assessment

The primary outcome measure was all-cause mortality at ten years. Vital status data were collected using linked national electronic records from the Office of National Statistics. Final censorship occurred on the 23rd of October 2024. For our sensitivity analysis looking at the associations with deprivation by period of

enrolment, duration of follow up was limited to 10 years to ensure equal follow up durations.

Actuarial survival predictions were derived from the UK National Life Tables (UK-NLT), an official survival estimation measure produced by the Human Mortality database.[17] The UK-NLT provide annual death rates by sex and age for any given year. This provides the baseline survival for members of the public with this age and sex, which we used as a reference control population.

Statistical analysis

Statistical analysis was performed using RStudio version 4.1.1. Analysis used the R suite 'tidyverse', while plots were compiled using the embedded 'ggplot2' package. Relative survival analysis was performed using the 'Survival' and 'Relsurv' packages. (<https://www.jstatsoft.org/article/view/v087i08>)

Patient characteristics are reported using the mean and standard deviation for continuous variables, with categorical variables summarised using the count of each class and the percentage of the dataset it represents. Unadjusted cumulative mortality rates describing the observed cohort survival were calculated and stratified by deprivation tertile. Relative survival data were illustrated with excess mortality rate (defined as the observed mortality rate minus the expected age–sex matched mortality rate in the general population defined by the UK-NLT) and by calculating excess loss of life expectancy stratified by deprivation tertile, and according to period of recruitment. Recruitment period was split into periods of three consecutive

calendar years. Wald confidence intervals (CIs) are used for mortality rate, while 500 bootstrap samples are used to produce CIs for years of life lost, with ANOVA used to compare the mean years of life lost between periods of recruitment. Missing data were not imputed.

Results

We recruited 1802 patients who had a mean age of 69.6 years (SD 12.5) and 1319 (73.2%) were male. Descriptive data comparing demographics, comorbidities, symptom severity and HF management by socioeconomic deprivation tertiles are shown in Table 1. Patients from areas of higher socioeconomic deprivation were more likely to be younger, male, have greater body mass index (BMI) be of black, Asian or minority ethnicity and have chronic obstructive pulmonary disease. Moreover, they had greater symptom burden and were less likely to receive cardiac implantable electronic device therapy.

Across differing recruitment periods from earliest to latest, patients were broadly older at presentation, less likely to have HF due to an ischaemic aetiology, had greater beta-blocker use at higher doses and had a lower burden of symptoms irrespective of socioeconomic status (Additional file 1: table S1-S3). Use of cardiac resynchronisation therapy (CRT) and implantable cardiac defibrillators (ICD) decreased over time in all groups. Mineralocorticoid receptor antagonist use significantly decreased over time only in patients from areas with higher socioeconomic deprivation (Additional file 1: table S3).

	Total Population (n=1802)	Tertile 1 (n=600)	Tertile 2 (n=601)	Tertile 3 (n=601)	P value
Age, years	69.6 (12.5)	71.3 (11.5)	70.5 (12.2)	67.0 (13.3)	0.002
Male, y/n	1319 (73.2)	468 (78.0)	437 (72.7)	414 (68.9)	0.005
IMD score	26.6 (18.6)	8.8 (3.1)	21.4 (5.7)	49.6 (10.9)	<0.001
BMI, kg/m ²	28.1 (6.0)	27.2 (4.9)	28.5 (5.4)	28.6 (7.6)	<0.001
BAME, y/n	71 (3.9)	22 (3.7)	16 (2.7)	33 (5.4)	0.037
Ischaemic aetiology, y/n	1067 (59.2)	366 (61.0)	356 (59.2)	345 (57.4)	0.547
Diabetes, y/n	504 (28.0)	151 (25.2)	166 (27.6)	187 (31.1)	0.070
COPD, y/n	284 (15.8)	72 (12.0)	99 (16.4)	113 (18.8)	0.003
CKD 4 or above, y/n	141 (7.8)	44 (7.3)	43 (7.2)	54 (9.0)	0.422
NYHA Class 3/4, y/n	555 (30.8)	161 (26.6)	183 (30.7)	211 (35.2)	0.005
LVEF, %	32 (9)	31 (9)	32 (10)	32 (10)	0.468
QRS, ms	123 (31)	127 (31)	125 (31)	118 (29)	0.090
SBP, mmHg	122 (22)	121 (21)	123 (21)	123 (23)	0.261
DBP, mmHg	71 (11)	71 (11)	71 (11)	72 (12)	0.186
HR, bpm	75 (16)	74 (15)	75 (16)	76 (16)	0.748
Betablocker, y/n	1523 (84.7)	529 (87.4)	488 (82.2)	506 (84.5)	0.039
Bisoprolol equivalent dose, mg	3.9 (3.4)	4.1 (3.4)	3.7 (3.2)	3.8 (3.4)	0.260
ACEi/ARB y/n	1626 (90.4)	558 (92.2)	524 (88.2)	544 (90.8)	0.057
Ramipril equivalent dose, mg	4.9 (3.5)	5.1 (3.5)	4.8 (3.6)	4.9 (3.5)	0.910
Loop diuretic y/n	1340 (74.6)	459 (75.9)	444 (74.4)	442 (74)	0.669
Furosemide equivalent dose, mg	51 (50)	52 (50)	49 (46)	52 (51)	0.644
MRA y/n	689 (38.3)	235 (38.8)	219 (36.9)	235 (39.2)	0.667
CRT y/n	455 (25.3)	181 (29.9)	154 (25.8)	120 (20)	<0.001
ICD y/n	210 (11.7)	95 (15.7)	65 (10.9)	50 (8.3)	<0.001

Table 1 – Baseline characteristics by socioeconomic deprivation tertile. Continuous data is presented as mean and standard deviation (SD). Categorical data is n (%). P value for continuous variables from ANOVA and categorical variables from Chi² testing respectively. Abbreviations: angiotensin converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB), Black, Asian, and Minority Ethnic (BAME), beats per minute (BPM), body mass index (BMI), cardiac resynchronisation therapy (CRT), chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), diastolic blood pressure (DBP), heart rate (HR), implantable cardiac defibrillator (ICD), index of Multiple Deprivation (IMD), left ventricular ejection fraction (LVEF), mineralocorticoid receptor antagonist (MRA), milligram (mg), New York Heart failure Association (NYHA), systolic blood pressure (SBP).

Association with outcome

During a median follow-up of 5.0 years (25th to 75th centile: 2.7-7.5), a total of 1,302 participants (72.3%) died. The unadjusted cumulative mortality rates were similar across tertiles of socioeconomic deprivation; however, by ten years of follow-up, mortality was nominally highest in tertile 2 (Figure 1). To quantify differences in excess mortality risk by socioeconomic deprivation, we constructed relative survival models. We observed a stepwise increase in excess mortality risk across the socioeconomic deprivation tertiles, with participants in tertile 3 (representing the most socioeconomic deprivation) having the greatest excess mortality risk (Figure 2 and Table 2). After 10 years, the excess mortality risk for participants in IMD tertile 3 relative to the general population was 24.2% (95% CI: 19.4%-28.9%), compared to 11.1% (95% CI: 6.1%-16.1%) for IMD tertile 1 (Table 2).

In terms of years of life lost, participants in tertile 1 (lowest deprivation) experienced a cumulative loss of 1.76 years (95% CI: 1.50–2.03), while those in IMD tertile 3 experienced the highest cumulative loss, with 2.30 years (95% CI: 2.03–2.57), a difference of 6.5 months over a 10-year period (Figure 3, Table 2). Moreover, whilst there was no statistically significant difference in life lost over a 10-year period by IMD tertile in the first and second recruitment periods, during final recruitment period participants in IMD tertile 1 lost significantly less life at ten years compared to those in IMD tertiles 2 and 3 (Figure 4).

1





Figure 1 - Unadjusted cumulative mortality of study cohort by socio-economic deprivation tertile.



2 Figure 2 – Excess mortality rate of study cohort by socio-economic deprivation tertile.

Excess mortality risk during specified period, % (95% CI)			
	Three years	Five years	Ten years
Tertile 1	4.9% (95 % CI: 1.3 – 8.7)	6.9% (95% CI: 2.4 – 11.3)	11.1% (95% CI: 6.1-16.1)
Tertile 2	8.1% (95% CI: 4.3 – 11.9)	12.6% (95% CI: 8.1 – 17.1)	17.6% (95% CI: 12.7-22.6)
Tertile 3	12.6% (95% CI: 8.8 - 16.3)	17.5% (95% CI: 13.1 - 21.7)	24.2% (95% CI: 19.4-28.9)
Years of life lost during specified period, years (95% CI)			
	Three years	Five years	Ten years
Tertile 1	0.22 (95% CI: 0.15-0.28)	0.56 (95% CI: 0.44-0.69)	1.76 (95% CI: 1.50-2.03)
Tertile 2	0.29 (95% CI: 0.22-0.36)	0.73 (95% CI: 0.60-0.86)	2.14 (95% CI: 1.86-2.41)
Tertile 3	0.29 (95% CI: 0.23-0.36)	0.77 (95% CI: 0.65-0.90)	2.30 (95% CI: 2.03-2.57)

Table 2 – Relative survival by socioeconomic deprivation tertile. Relative survival is expressed as % excess mortality risk and years of life expectancy lost relative to age and sex matched UK population with 95% confidence intervals (CI).




Figure 3 – Years of life expectancy lost of study cohort by socioeconomic deprivation tertile.




Figure 4 – Years of life expectancy lost by socioeconomic deprivation tertile by study recruitment period at ten years follow up duration. Statistical significance was assessed using ANOVA across study recruitment periods. Abbreviations: not significant (ns), * p<0.05

Discussion

We present a comprehensive analysis of the effects of socioeconomic deprivation on survival in relation to actuarial predictions in a large, unselected cohort of patients with HF. By considering actuarial estimates of survival, we have shown a direct relation between socio-economic deprivation and all-cause mortality, with patients from areas of high socio-economic deprivation losing 2.30 years of life compared to the age and sex matched general population over a ten-year period. Moreover, there appears to be a widening disparity in the effects of socio-economic deprivation on survival in relation to actuarial predictions over time, with patients with HF from the least deprived areas losing significantly less life over the recruitment period compared to those from areas with higher socioeconomic deprivation.

We have previously shown that patients with HF have a 2.4-fold excess loss of life compared to an age and sex matched general population. [14] Moreover, prior studies have demonstrated an inverse relation between socioeconomic deprivation and disease-free survival in patients with HF; [18–20] a phenomenon driven by increased risk of non-cardiovascular mortality and hospitalisation. [5] No study has quantified the effects of socioeconomic deprivation on survival in relation to actuarial predictions amongst patients with HF.

Multimorbidity amongst patients with HF is common and more prevalent in patients from areas of higher socioeconomic deprivation, [21,22] and may account for part of the adverse association between socioeconomic deprivation and mortality. [23] Co-morbidity adds complexity to the management of HF, as it can make diagnosis more difficult, prescribing guideline-directed medical therapy more challenging and augurs a worse prognosis. [24] Co-morbidities more frequently accrue at a younger age in patients with HF from areas of higher socioeconomic deprivation [2], which we also observed in our study with patients in the most deprived group were younger and had the greatest prevalence of chronic obstructive pulmonary disease and diabetes. Younger patients have the largest potential number of years of life expectancy to lose, and the greatest potential for life expectancy gained with effective medical therapy, [25] and this may explain the differences in survival seen in our cohort. In addition, patients from the most deprived areas in our study were least likely to receive device therapy and were the only group to see a significant reduction in the use of mineralocorticoid receptor antagonists over the study period; both findings are in keeping with observational data from the USA. [26,27]

We observed an apparent worsening of disparity in actuarial survival by socioeconomic status over time, with only patients from areas with lower socioeconomic deprivation seeing a reduction in loss of years of life expectancy across recruitment period. In the only other study reporting the temporal effects of socioeconomic status on heart failure mortality, Taylor *et al* demonstrated in a cohort of 55 959 primary care patients with a new diagnosis of HF, that whilst there was little difference between one and five-year survival in the most deprived and least deprived groups over the study period, ten-year survival was significantly lower in the

1 most deprived group. [3] However, this study did not formally classify HF based on
2 systolic function and the HF diagnosis was derived from GP coding. In addition, it
3 only included patients in primary care who may have a different prognosis to those
4 being managed in the hospital setting.

5
6 The reasons behind this widening disparity are not clear. The present study was
7 conducted during a period where there was significant change within UK health care
8 policy, amongst a wider context of economic austerity. [28] Between 2009 and 2011,
9 public expenditure within the UK was cut by 2.2%. [29] Although expenditure on
10 overall healthcare was protected, social care, local government and income support
11 were not protected and cuts to these areas have direct and indirect effects on health,
12 including increasing unemployment, poverty, and homelessness. [29,30] These
13 policies disproportionately impact people of lower socioeconomic status, [31] and
14 during this period of austerity, all-cause mortality rates increased across the UK,
15 particularly amongst those in the UK from areas of higher socioeconomic
16 deprivation. [32] Our results reflect this pattern and austerity may in part be
17 responsible for this widening disparity.

18
19 Tackling the impact of socioeconomic deprivation on health is complex and requires
20 a multi-level approach. [7] At the system level, increasing funding and resource
21 allocation to facilities serving socioeconomically deprived populations is critical to
22 address disparities in access to care. [33] Additionally, educating healthcare
23 providers on the social determinants of health can help them better understand the
24 context of their patients' lives. [34] Encouraging shared decision-making practices

enables patients, regardless of their health literacy levels, to actively participate in their care, fostering greater equity in outcomes.[35]

Patients from areas of higher-socioeconomic deprivation are historically underrepresented in HF randomised controlled trials and analyses by socioeconomic status is not routinely reported. [36] Although there is no biological reason to believe the effect of HF therapies varies across socioeconomic strata, other factors such as medical compliance and healthcare access are influenced by socioeconomic status and could potentially interact with treatment efficacy. [36] To address this, initiatives should be established to widen and promote trial recruitment of people from areas of lower socioeconomic status and reporting of treatment effects according to socioeconomic status should be mandatory.

Effective communication with patients and relatives regarding disease prognosis is reliant on the application and understanding of survival statistics. [37] More widely used measures of survival including hazard ratio, relative and absolute risk do not account for the expected rate of death of the general population without disease, nor reflect the reality that life is finite. In addition, patients with HF frequently overestimate their life expectancy compared to model-based predictions, particularly those patients with more severe disease, [38] whilst repeated and prolonged hospital admission is common amongst patients with HF towards the last year of life. [39] Therefore, the ability to provide more nuanced and understandable illustrations of disease prognosis to patients with HF using relative survival measures, may help facilitate advanced care planning discussions and ensure patients have realistic expectations of their disease prognosis. [12]

Strengths and limitations

First, IMD is a measure of area-based deprivation and does not reflect the deprivation of an individual, so some patients' personal socioeconomic deprivation may have been over or underestimated. Second, participants were recruited before the widespread use of other disease modifying therapies for HF including angiotensin receptor/neprilysin inhibitors and sodium glucose co-transporter inhibitors which may improve cardiovascular outcomes. Therefore, our survival estimates may be lower than contemporary estimates. [40,41] In addition, our estimates do not reflect or account for quality of life, merely the number of years of life expectancy lost. Our analysis stratifies participants and inherently accounts for two strong predictors of mortality, age and biological sex, using population life tables. But we did not adjust for other covariates such as medication use, ethnicity, comorbidities, or physical characteristics. However, these features are key components of socioeconomic status and reflect important mechanisms through which socioeconomic status affects health outcomes. Adjusting for these factors could obscure their contribution to the disparities observed between socioeconomic strata, as they are intrinsic to the effects of deprivation. Finally, our study used expected survival data from the UK and our estimates may not be generalisable to the rest of the world.

Conclusions

We have shown that rising socioeconomic deprivation is associated with incremental loss of life expectancy amongst patients with HF. In addition, there is evidence of

1 widening disparity in the amount of life expectancy lost between socio-economic
2 groups. Our data provides understandable and quantifiable estimates of loss of life
3 expectancy for patients with HF and may help facilitate more nuanced conversations
4 regarding advanced care planning. Future research should explore whether targeted
5 interventions in health, social, and economic policy can reduce the socioeconomic
6 disparities in survival observed among patients with HF.

7

1 **Abbreviations**

2

3 ACEI – Angiotensin converting enzyme inhibitor

4 ARB - Angiotensin receptor blocker

5 BAME – Black, Asian and Minority Ethnic

6 BMI – Body Mass index

7 BPM – Beats per minute

8 CI – Confidence interval

9 CKD – Chronic kidney disease

10 COPD – Chronic obstructive pulmonary disease

11 CRT – Cardiac resynchronisation therapy

12 DBP – Diastolic blood pressure

13 HF - Heart failure

14 HFrEF - Heart failure with reduced ejection fraction

15 HR – Heart rate

16 ICD – Implantable cardiac defibrillator

17 IMD - Index of multiple deprivation

18 LVEF – Left ventricular ejection fraction

19 MRA - Mineralocorticoid receptor antagonist

20 NYHA – New York Heart Association

21 SBP – Systolic blood pressure

22 SD – Standard deviation

23 UK - United Kingdom

24 UKH2 - United Kingdom Heart Failure Evaluation and Assessment of Risk Trial

UK-NLT2 - UK National Life Tables

Declarations

Ethics approval and consent to participate: Ethical approval of the study was granted by the Leeds West Research Ethics Committee prior to study commencement (07/Q1205/17). All participants signed informed consent in accordance with the Declaration of Helsinki.

'Authors' Twitter handles

@ollybrown, @drmikedrozd, @drsamstraw, @maria_paton, @RicCubbon

Consent for publication: Not applicable

Data availability: The datasets generated and/or analysed during the current study are not publicly available due to the inclusion of potentially identifiable information but are available from the corresponding author upon reasonable request.

Competing interests: SS has received speaker's fees, honoraria and non-financial support from Astra Zeneca. MFP has received consultancy fees from Astra Zeneca. RC has received speaker's fees from Janssen Oncology. OIB has received speaker's fees and honoraria from Novartis.

Funding: This research was funded by the British Heart Foundation (RG/F/22/110076).

Authors' Contributions: OIB and MTK conceived the study. SS, MM, RB, ADS, VKG, AS, AMNW, CS, KKW, RMC and MTK collected the data. OIB, MD and RMC undertook statistical analysis. OIB, MD and MTK produced the first version of the manuscript. HM, MFP, KIB, JG and RMC provided critical oversight of the manuscript. All authors read and approved the final version of the manuscript.

Additional Files:

Additional File 1: Tables S1-S3 contains tables demonstrating clinical characteristics of socioeconomic deprivation tertiles over study period.

Table S1- Characteristics of socioeconomic deprivation tertile 1 over study period.

Table S2 – Characteristics of socioeconomic deprivation tertile 2 over study period.

Table S3 – Characteristics of socioeconomic deprivation tertile 3 over study period.

References

1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2021; 42: 3599–726.
2. Conrad N, Judge A, Tran J, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. *Lancet*. 2018; 391: 572–80.
3. Taylor CJ, Ordóñez-Mena JM, Roalfe AK, et al Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study. *BMJ*. 2019; 364: l223.
4. Nadarajah R, Farooq M, Raveendra K, et al. Inequalities in care delivery and outcomes for myocardial infarction, heart failure, atrial fibrillation, and aortic stenosis in the United Kingdom. *Lancet Reg*. 2023; 33: 100719.
5. Witte KK, Patel PA, Walker AMN, et al. Socioeconomic deprivation and mode-specific outcomes in patients with chronic heart failure. *Heart*. 2018; 104: 993–8.
6. Hawkins NM, Jhund PS, McMurray JJV, et al. Heart failure and socioeconomic status: accumulating evidence of inequality. *Eur J Heart Fail*. 2012; 14: 138–46.
7. Kilbourne AM, Switzer G, Hyman K, et al. Advancing health disparities research within the health care system: a conceptual framework. *Am J Public Health*. 2006; 96: 2113–21.

- 1 8. McMaughan DJ, Oloruntoba O, Smith ML. Socioeconomic Status and Access
2 to Healthcare: Interrelated Drivers for Healthy Aging. *Front Public Health*.
3 2020; 8: 231
- 4 9. Vaccarella S, Georges D, Bray F, et al. Socioeconomic inequalities in cancer
5 mortality between and within countries in Europe: a population-based study.
6 *Lancet Reg*. 2023; 25: 100551.
- 7 10. Brandt EJ, Tobb K, Cambron JC, et al, Watson K. Assessing and Addressing
8 Social Determinants of Cardiovascular Health: JACC State-of-the-Art Review.
9 *J Am Coll Cardiol*. 2023; 81: 1368–85.
- 10 11. Brown OI, Drozd M, McGowan H, et al. Relationship Among Diabetes,
11 Obesity, and Cardiovascular Disease Phenotypes: A UK Biobank Cohort
12 Study. *Diabetes Care*. 2023; 46: 1531–40.
- 13 12. Schultz WM, Kelli HM, Lisko JC, et al. Socioeconomic Status and
14 Cardiovascular Outcomes. *Circulation*. 2018; 137: 2166–78.
- 15 13. Allen LA, Yager JE, Funk MJ, et al. Discordance between patient-predicted
16 and model-predicted life expectancy among ambulatory patients with heart
17 failure. *JAMA*. 2008; 299: 2533–42.
- 18 14. Drozd M, Relton SD, Walker AMN, et al. Association of heart failure and its
19 comorbidities with loss of life expectancy. *Heart*. 2021; 107: 1417–21.
- 20 15. Walker AMN, Drozd M, Hall M, et al. Prevalence and Predictors of Sepsis
21 Death in Patients With Chronic Heart Failure and Reduced Left Ventricular
22 Ejection Fraction. *J Am Heart Assoc*. 2018; 7: e009684.
- 23 16. Cubbon RM, Gale CP, Kearney LC, et al. Changing characteristics and mode
24 of death associated with chronic heart failure caused by left ventricular systolic

- dysfunction: a study across therapeutic eras. *Circ Heart Fail*. 2011; 4: 396–403.
17. Human Mortality Database. <https://www.mortality.org/Home/Index>. Accessed online: 5 November 2024.
18. Ge Y, Zhang L, Gao Y, et al. Socio-economic status and 1 year mortality among patients hospitalized for heart failure in China. *ESC Heart Fail*. 2022; 9: 1027–37.
19. Vinter N, Fawzy AM, Gent D, et al. Social determinants of health and cardiovascular outcomes in patients with heart failure. *Eur J Clin Invest*. 2022; 52: e13843.
20. Schrage B, Lund LH, Benson L, et al. Lower socioeconomic status predicts higher mortality and morbidity in patients with heart failure. *Heart*. 2021; 107: 229–36.
21. MacGowan H, Brown OI, Drozd M, et al. Comorbidity trajectories before and after the diagnosis of heart failure: a UK Biobank cohort study. *Eur J Heart Fail*. 2025. doi: 10.1002/ejhf.3601
22. Head A, Birkett M, Fleming K, et al. Socioeconomic inequalities in accumulation of multimorbidity in England from 2019 to 2049: a microsimulation projection study. *Lancet Public Health*. 2024; 9: e231–9.
23. Foraker RE, Rose KM, Suchindran CM, et al. Socioeconomic status, Medicaid coverage, clinical comorbidity, and rehospitalization or death after an incident heart failure hospitalization: Atherosclerosis Risk in Communities cohort (1987 to 2004). *Circ Heart Fail*. 2011; 4: 308–16.
24. Gerhardt T, Gerhardt LMS, Ouwerkerk W, et al. Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-

- HF): a prospective, multicentre, global cohort study. *Lancet Glob Health*. 2023; 11: e1874–84.
25. Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. *Lancet*. 2020; 396: 121–8.
26. Schjødt I, Johnsen SP, Strömberg A, et al. Socioeconomic Factors and Clinical Outcomes Among Patients With Heart Failure in a Universal Health Care System. *JACC Heart Fail*. 2019; 7: 746–55.
27. Farmer SA, Tuohy EJ, Small DS, et al. Impact of community wealth on use of cardiac-resynchronization therapy with defibrillators for heart failure patients. *Circ Cardiovasc Qual Outcomes*. 2012; 5: 798–807.
28. Stuckler D, Reeves A, Loopstra R, et al. Austerity and health: the impact in the UK and Europe. *Eur J Public Health*. 2017; 27: 18–21.
29. Reeves A, Basu S, McKee M, et al. Austere or not? UK coalition government budgets and health inequalities. *J R Soc Med*. 2013; 106: 432–6.
30. Watt T, Charlesworth A, Gershlick B. Health and care spending and its value, past, present and future. *Future Healthc J*. 2019; 6: 99–105.
31. Stuckler D, Reeves A, Loopstra R, et al. Austerity and health: the impact in the UK and Europe. *Eur J Public Health*. 2017; 27: 18–21.
32. Walsh D, Dundas R, McCartney G, et al. Bearing the burden of austerity: how do changing mortality rates in the UK compare between men and women? *J Epidemiol Community Health*. 2022; 76: 1027–33.

- 1 33. Barr B, Bambra C, Whitehead M. The impact of NHS resource allocation policy
2 on health inequalities in England 2001-11: longitudinal ecological study. *BMJ*.
3 2014; 348: g3231.
- 4 34. Glenn J, Kleinhenz G, Smith JMS, et al. Do healthcare providers consider the
5 social determinants of health? Results from a nationwide cross-sectional study
6 in the United States. *BMC Health Serv Res*. 2024; 24: 271.
- 7 35. Committee on Educating Health Professionals to Address the Social
8 Determinants of Health; Board on Global Health; Institute of Medicine; National
9 Academies of Sciences, Engineering, and Medicine. A Framework for
10 Educating Health Professionals to Address the Social Determinants of Health.
11 Washington (DC): National Academies Press (US); 2016.
- 12 36. Baudry G, Monzo L, Petrie MC, et al. Consistency of HFrEF treatment effect in
13 underrepresented groups in randomized clinical trials. *npj Cardiovascular*
14 *Health*. 2024; 1: 27.
- 15 37. Belot A, Ndiaye A, Luque-Fernandez M-A, et al. Summarizing and
16 communicating on survival data according to the audience: a tutorial on
17 different measures illustrated with population-based cancer registry data. *Clin*
18 *Epidemiol*. 2019; 11: 53–65.
- 19 38. Allen LA, Yager JE, Funk MJ, et al. Discordance between patient-predicted
20 and model-predicted life expectancy among ambulatory patients with heart
21 failure. *JAMA*. 2008; 299: 2533–42.
- 22 39. Abel AAI, Samuel NA, Cuthbert JJ, et al. Hospital admissions in the last year
23 of life of patients with heart failure. *Eur Heart J Qual Care Clin Outcomes*.
24 2024; 10: 168–75.

- 1 40. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with
2 Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019; 381: 1995–
3 2008.
- 4 41. McMurray JJV, Packer M, Desai AS, et al, PARADIGM-HF Investigators and
5 Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure.
6 N Engl J Med. 2014; 371: 993–1004.